Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Goodrx Holdings Inc(GDRX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for GDRX
10/02/2026: GDRX (2-star) is currently NOT-A-BUY. Pass it for now.
GoodRx Holdings is a health technology company that operates a digital platform for prescription drug price comparison and related telehealth services. Its primary strength lies in a widely used discount card and a robust network of pharmacy partnerships that simplify a fragmented pharmaceutical market. The company is currently shifting its growth strategy toward provider-facing solutions and advertising services for drug manufacturers to diversify its income. Key risks include intense competition from large retail pharmacy chains and potential regulatory changes affecting pharmacy benefit management models. GoodRx may suit growth-oriented investors, though it remains a volatile asset requiring close monitoring of platform engagement and regulatory developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | While the company operates in a large addressable market, recent growth rates have moderated significantly. |
| Momentum investor | Weak fit | The stock has largely lacked consistent bullish momentum, making it less attractive for trend-following strategies. |
| Value investor | Mixed fit | Valuation has compressed significantly from IPO levels, but earnings quality remains sensitive to regulatory shifts. |
| Dividend investor | Weak fit | GoodRx does not pay a dividend and prioritizes internal reinvestment. |
| Low-risk investor | Weak fit | High sensitivity to regulatory and competitive risks leads to volatility inconsistent with low-risk goals. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock often experiences sharp price swings related to regulatory news or quarterly results. |
| Valuation risk | Medium | Market sentiment can shift rapidly regarding the company's long-term growth prospects. |
| Competition risk (e.g. Retail Pharmacy) | High | Major pharmacy chains and tech platforms are increasingly competing directly in the discount space. |
| Business quality | Medium | While the platform has strong network effects, it remains dependent on third-party PBM relationships. |
| Dividend income | Low / none | Investors should not expect any income from this security. |
| Execution risk | Medium | Successfully pivoting toward provider-focused and manufacturer solutions is critical for long-term health. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -30.54% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/02/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.12B USD | Price to earnings Ratio 54.5 | 1Y Target Price 3.95 |
Price to earnings Ratio 54.5 | 1Y Target Price 3.95 | ||
Volume (30-day avg) 1.1M shares | Beta 1.6 | 52 Weeks Range 1.77 - 5.81 | Updated Date 10/02/2026 |
52 Weeks Range 1.77 - 5.81 | Updated Date 10/02/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.06 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Prescription Transactions | Fees earned from PBMs for transactions processed through the GoodRx platform. | The main engine of revenue; GoodRx gets paid when people use its coupons at the pharmacy. |
| Subscription Services | Monthly membership fees from GoodRx Gold members. | Provides stable, recurring subscription revenue. |
| Pharma Manufacturer Solutions | Advertising and access program fees from drug manufacturers. | A growing segment where pharmaceutical companies pay to reach patients. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE 54.5 | Forward PE 10.29 | Enterprise Value 1.38B | Price to Sales(TTM) 1.42 |
Enterprise Value 1.38B | Price to Sales(TTM) 1.42 | ||
Enterprise Value to Revenue 1.75 | Enterprise Value to EBITDA 8.05 | Shares Outstanding 107.18M | Shares Floating 93.97M |
Shares Outstanding 107.18M | Shares Floating 93.97M | ||
Percent Insiders 12.71 | Percent Institutions 55.84 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Goodrx Holdings Inc
Exchange NASDAQ | Headquarters Santa Monica, CA, United States | ||
IPO Launch date 2020-09-23 | President, CEO & Director Ms. Wendy Barnes | ||
Sector Healthcare | Industry Health Information Services | Full time employees 697 | Website https://www.goodrx.com |
Full time employees 697 | Website https://www.goodrx.com | ||
GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscription programs and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. In addition, the company provides healthcare products and solutions for dogs, cats, and other pets. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.